It's end-of-the-year time again, and like a lot of publications, EuroPharma Today is taking stock of 2009 - remembering which stories were naughty, and which were nice - and planning ahead for New Year's resolutions in 2010.
In case you missed any of them, we have assembled a baker's dozen of our most-read stories from 2009. From risk-sharing deals to biosimilars to unique launches in Europe, our top stories of 2009 reflect the hottest issues impacting the European pharma industry.
Thank you for reading EuroPharma Today, and we wish you happy holidays and a wonderful new year.
Sincerely, The Editors
P.S. Do you follow EuroPharma Today on Twitter?
Our Most-Read Stories of 2009
- No U.S. Liraglutide News From Novo, But Victoza European Rollout Continues
- Irish Biotech Elan Loses Tysabri Court Case To Biogen
- Generic Lovenox In EU Will Require Clinical Data, Shrinking Sandoz's Opportunity
- More Velcade-Style Risk-Sharing In The UK?
- FDA And EMEA: Minding The Gap
- New Brand, Same MS Drug: Novartis Launches Extavia In Europe
- Acquiring Pharmaceutical Companies And Business In Germany
- Sanofi Hands Back TroVax To Oxford BioMedica, Signs Eye Deal
- In Europe, Centralized OTC Switch Still Has A Few Bugs
- European Biosimilars' Market Performance Mirrors US Legislative Progress: Slow But Steady
- European Industry, Authorities Claim Minor Manufacturing Changes Still Burdensome To Report Under Revised Regulation
- Danish Biotech Genmab In Trouble As Arzerra Disappoints In NHL
- Solvay Confirms It Is Looking At Options - But For All Of Its Businesses
